KAYTUS
KAYTUS, a leading IT infrastructure provider, launched at ISC High Performance 2024 the K22V2, a multi-node server with exceptional compute density and energy efficiency. The K22V2 integrates two independent hot-swap single-socket compute nodes in a 2U form factor. Each node supports either a 4th Gen AMD EPYC™ 9004 series processor with 12 DDR5 RDIMMs (4800MHz) or a 5th Gen Intel® Xeon® processor with eight DDR5 RDIMMs (5600MHz), offering flexible storage and I/O configurations. Each node also supports 6 SATA/NVMe SSDs or 8 E1.S SSDs, along with 4 PCIe 5.0 slots and one OCP NIC 3.0. This makes it an optimal choice for compute-intensive applications, suitable for customers seeking both high compute density and cooling efficiency.
Advanced 1U Computing Density Enhanced by 2U Cooling and O&M Efficiency
Focused on energy efficiency, K22V2 is fitted to accommodate two single-socket nodes within a 2U space, in a horizontal layout. Each node functions as an autonomous server system, enabling independent hot maintenance with plug-and-play support to minimize disruption, thus significantly enhancing O&M efficiency. This design is advantageous for opting for 2U high efficiency heatsinks. A 2U heatsink, due to its effective utilization of vertical space, features a length merely one-fifth that of a 1U heatsink, facilitating a more efficient server layout. Furthermore, the air flow resistance of a 1U heatsink is four times that of a 2U counterpart at the same air volume (50 CFM), necessitating fans with higher power.
According to testing data, the cooling efficiency of the server in a 2U space is superior when two single-socket nodes are horizontally arranged in parallel compared to when two 1U single-socket nodes are vertically stacked. The K22V2 demonstrates 40% better cooling efficiency compared to two standard 1U rack servers under the same computing conditions, while also reducing power consumption by up to 8%.
New pioneering architecture delivers better cost performance efficiency
The K22V2 server features a streamlined modular design where two nodes share the chassis, backplane, fan, and PSU, providing significant L6 cost advantages compared to products with two independent nodes. This pioneering architecture is optimized for high-performance single-socket processors and addresses the issue of high migration costs associated with a single server failure impacting multiple tasks. Consequently, the K22V2 is versatile, supporting a wide range of typical applications from computing to big data, and is ideal for scenarios requiring demanding computing density and cooling efficiency. Additionally, it offers users more convenient O&M.
System Overview |
KAYTUS K22V2 Multi-node server (Side by side) |
Normal 2x 1U servers (Stack up) |
System Configuration |
||
System depth |
880 mm |
850 mm |
CPU Heatsink |
2U EVAC |
1U EVAC |
Fan |
6056*6 |
4056*8 |
CPU Power (EGS) |
300W |
300W |
CPU Core Count |
104 |
208 |
Thermal Evaluation Result |
||
Fan Duty |
50% |
70% |
Total Fan Power |
83.6W |
268.8W |
Fan Power/Per CPU |
41.8W |
67.2W |
Note |
All thermal evaluations are based on conditions of a 35°C ambient temperature, sea level, and a normally operating fan. |
|
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523837473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom